Home > Publications database > Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study. > print |
001 | 296085 | ||
005 | 20250103121049.0 | ||
024 | 7 | _ | |a 10.1016/j.lungcan.2024.108072 |2 doi |
024 | 7 | _ | |a pmid:39740425 |2 pmid |
024 | 7 | _ | |a 0169-5002 |2 ISSN |
024 | 7 | _ | |a 1872-8332 |2 ISSN |
037 | _ | _ | |a DKFZ-2025-00033 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Aguado-Barrera, Miguel E |b 0 |
245 | _ | _ | |a Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study. |
260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1735825548_23499 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies.Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses.We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91).Our findings indicate strong alignment between healthcare professionals' and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception. |
536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
650 | _ | 7 | |a Correlation measures |2 Other |
650 | _ | 7 | |a Fatigue |2 Other |
650 | _ | 7 | |a Lung cancer |2 Other |
650 | _ | 7 | |a Patient reported outcome measures |2 Other |
650 | _ | 7 | |a Quality of life |2 Other |
650 | _ | 7 | |a Radiation effects |2 Other |
650 | _ | 7 | |a Symptom assessment |2 Other |
700 | 1 | _ | |a Lopez-Pleguezuelos, Carlos |b 1 |
700 | 1 | _ | |a Gómez-Caamaño, Antonio |b 2 |
700 | 1 | _ | |a Calvo-Crespo, Patricia |b 3 |
700 | 1 | _ | |a Taboada-Valladares, Begoña |b 4 |
700 | 1 | _ | |a Azria, David |b 5 |
700 | 1 | _ | |a Boisselier, Pierre |b 6 |
700 | 1 | _ | |a Briers, Erik |b 7 |
700 | 1 | _ | |a Chan, Clara |b 8 |
700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 9 |u dkfz |
700 | 1 | _ | |a Coedo-Costa, Carla |b 10 |
700 | 1 | _ | |a Crujeiras-González, Ana |b 11 |
700 | 1 | _ | |a Cuaron, John J |b 12 |
700 | 1 | _ | |a Defraene, Gilles |b 13 |
700 | 1 | _ | |a Elliott, Rebecca M |b 14 |
700 | 1 | _ | |a Faivre-Finn, Corinne |b 15 |
700 | 1 | _ | |a Franceschini, Marzia |b 16 |
700 | 1 | _ | |a Fuentes-Rios, Olivia |b 17 |
700 | 1 | _ | |a Galego-Carro, Javier |b 18 |
700 | 1 | _ | |a Gutiérrez-Enríquez, Sara |b 19 |
700 | 1 | _ | |a Heumann, Philipp |0 P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753 |b 20 |u dkfz |
700 | 1 | _ | |a Higginson, Daniel S |b 21 |
700 | 1 | _ | |a Johnson, Kerstie |b 22 |
700 | 1 | _ | |a Lambrecht, Maarten |b 23 |
700 | 1 | _ | |a Lang, Philippe |b 24 |
700 | 1 | _ | |a Lievens, Yolande |b 25 |
700 | 1 | _ | |a Mollà, Meritxell |b 26 |
700 | 1 | _ | |a Ramos, Mónica |b 27 |
700 | 1 | _ | |a Rancati, Tiziana |b 28 |
700 | 1 | _ | |a Rattay, Tim |b 29 |
700 | 1 | _ | |a Rimner, Andreas |b 30 |
700 | 1 | _ | |a Rosenstein, Barry S |b 31 |
700 | 1 | _ | |a Sangalli, Claudia |b 32 |
700 | 1 | _ | |a Seibold, Petra |0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |b 33 |u dkfz |
700 | 1 | _ | |a Sperk, Elena |b 34 |
700 | 1 | _ | |a Stobart, Hilary |b 35 |
700 | 1 | _ | |a Symonds, Paul |b 36 |
700 | 1 | _ | |a Talbot, Christopher J |b 37 |
700 | 1 | _ | |a Vandecasteele, Katrien |b 38 |
700 | 1 | _ | |a Veldeman, Liv |b 39 |
700 | 1 | _ | |a Ward, Tim |b 40 |
700 | 1 | _ | |a Webb, Adam |b 41 |
700 | 1 | _ | |a Woolf, David |b 42 |
700 | 1 | _ | |a de Ruysscher, Dirk |b 43 |
700 | 1 | _ | |a West, Catharine M L |b 44 |
700 | 1 | _ | |a Vega, Ana |b 45 |
700 | 1 | _ | |a Consortium, REQUITE |b 46 |e Collaboration Author |
773 | _ | _ | |a 10.1016/j.lungcan.2024.108072 |g Vol. 199, p. 108072 - |0 PERI:(DE-600)2025812-4 |p 108072 |t Lung cancer |v 199 |y 2025 |x 0169-5002 |
909 | C | O | |o oai:inrepo02.dkfz.de:296085 |p VDB |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 33 |6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
914 | 1 | _ | |y 2025 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LUNG CANCER : 2022 |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b LUNG CANCER : 2022 |d 2023-10-24 |
920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)C020-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|